Fluoxetina Nodepe

Quick links to important sections

Fluoxetina Nodepe

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fluoxetina Nodepe

Quick Facts

Property Description
Active Ingredient Fluoxetine (as the hydrochloride salt)
Form Hard capsules, tablets, oral solution
Pharmacological Class Selective Serotonin Reuptake Inhibitor (SSRI)
Common Route Oral
Origin Synthetic compound

Defining Fluoxetina Nodepe: Classification and Composition

Fluoxetina Nodepe is a prescription-only pharmaceutical preparation containing the active ingredient, fluoxetine (fluoxetine hydrochloride). This compound is a synthetic entity classified as a Selective Serotonin Reuptake Inhibitor (SSRI), a group of medications recognized for treating neurochemical imbalances. Fluoxetine is structurally known for its relatively long half-life compared to some other agents in its class. The medication is prepared for oral administration and is typically presented as hard capsules or tablets, though liquid oral solution formulations are also available.


What is the General Purpose of Fluoxetina Nodepe?

Its general purpose is to provide pharmacological support for stabilizing mood regulation and fostering emotional stability in patients. The underlying mechanism involves enhancing neural communication by adjusting the balance of the neurotransmitter serotonin in the central nervous system. By acting as an SSRI, the medicine specifically inhibits the reabsorption of serotonin by nerve cells. This physiological action leads to increased serotonin availability in the synaptic cleft, which supports the body's systems in managing persistent emotional imbalance. This therapeutic approach is supported by pharmacological studies that confirm its role in stabilizing mood and emotional state.


How Does Fluoxetine Compare to Other Antidepressant Types?

Fluoxetine is characterized by its selective mechanism, focusing predominantly on the serotonin system. This selectivity is a key distinction from older medications, such as Tricyclic Antidepressants (TCAs), which affect a broader array of neurotransmitters. The SSRI class, and fluoxetine in particular, represents a more modern and focused approach to addressing neurochemical imbalances.

What side effects are possible with Fluoxetina Nodepe?

Possible side effects and safety information

The official safety profile of Fluoxetine (Fluoxetina Nodepe) is documented by governmental regulatory authorities like the FDA and EMA. Adverse effects are classified by frequency and grouped into System-Organ-Classes (SOC).

Frequency-Classified Adverse Reactions

The incidence of possible effects is categorized based on clinical trial and post-marketing data:

Classification Examples of Documented Adverse Events
Very Common (Affecting >1 in 10 people) Insomnia, Headache, Nausea, Diarrhea, Fatigue.
Common (Affecting 1 to 10 in 100 people) Anxiety, Tremor, Dizziness, Decreased appetite, Dry mouth, Sexual dysfunction.

Adverse reactions are organized into SOC categories, including Gastrointestinal disorders, Nervous system disorders, Psychiatric disorders, and Reproductive system disorders.

Serious Adverse Reactions and Safety Constraints

Regulatory documents mandate specific warnings for rare but serious adverse reactions. The FDA includes a Boxed Warning regarding the increased risk of Suicidal Ideation and Behavior in children, adolescents, and young adults (up to age 24), particularly during the initiation of treatment or following dosage adjustments.

Other serious events documented in regulatory labels include Serotonin Syndrome, severe Cutaneous Reactions (e.g., Stevens-Johnson Syndrome), and certain Cardiac Dysrhythmias (e.g., QT prolongation).

Safety constraints include a strict Contraindication for use with Monoamine Oxidase Inhibitors (MAOIs) due to the risk of Serotonin Syndrome. Use is also contraindicated with Pimozide or Thioridazine.

Population-specific safety considerations are noted for patients with Hepatic impairment, where a lower or less frequent dosage is required, and for Older Adults, who may be at a greater risk for conditions like Hyponatremia (low sodium levels).

Overdose and Emergency Response

Overdose and when to seek help — Official Regulatory Information for Fluoxetina Nodepe

Overdose Scope

Element Regulatory Statement
Documented overdose presentations Overdose manifestations reported in regulatory documents include seizures, sinus tachycardia, tremor, agitation, CNS hyperexcitability, nausea, and vomiting.
Physiological systems affected (as stated in label) Primarily the Central Nervous System and Cardiovascular System.
Dose-related or exposure-related factors (if applicable) The risk of severe toxicity and fatal outcomes is significantly increased in cases of co-ingestion with other serotonergic drugs or alcohol.
Population-specific overdose notes (if applicable) The long elimination half-lives of fluoxetine and its active metabolite require a prolonged observation period in overdose management.
Emergency-response statements (as written in official documents) Treatment is symptomatic and supportive. Necessary interventions include establishing and maintaining an airway. No specific antidote is known for fluoxetine overdose.
When immediate medical help is required (label-derived phrasing only) Individuals must seek immediate medical attention for any suspected overdose symptoms. The emergence of severe conditions like Serotonin Syndrome, ventricular arrhythmia, or coma necessitates urgent hospitalization.

Overdose Classifications (High-Level)

Classification Element Regulatory Statement
Severity classification (as defined in official documents) The profile includes documentation of life-threatening outcomes such as QT prolongation, Ventricular arrhythmia, seizures, and severe Serotonin Syndrome.
Regulatory basis (EMA / FDA / etc.) Information derived from government-authorized prescribing information for fluoxetine.
Overdose-context constraints (as defined in official documents) Management requires continuous cardiac monitoring (ECG) and prolonged observation.

Resulting Overdose Structure

Official Overdose Statements:

  • Overdose presentations include CNS hyperexcitability, sinus tachycardia, tremor, agitation, nausea, and vomiting.
  • Serious outcomes documented are Serotonin Syndrome, seizures, and life-threatening cardiac rhythm abnormalities, including QT prolongation.
  • Individuals must seek immediate medical attention for any suspected overdose event.
  • Management is strictly symptomatic and supportive, and no specific antidote is known.
  • Continuous cardiac monitoring is a mandated procedure due to the risk of documented cardiovascular effects.

Connection to the overall overdose profile (2–4 sentences): Regulatory documents establish the official overdose profile by detailing specific manifestations and severe risks associated with excess exposure, especially cardiac and neurological events. This information explicitly mandates seeking immediate medical attention for any suspicion of overdose and outlines the required supportive measures and the need for prolonged hospital observation and continuous cardiac monitoring.

Therapeutic Uses of Fluoxetina Nodepe

What Fluoxetina Nodepe Treats: Main Uses and Benefits

The core therapeutic function of Fluoxetina Nodepe is to provide supportive relief for symptoms across several major psychiatric domains, aiming to support general well-being during symptomatic phases. The medication is commonly used across conditions characterized by periods of heightened symptoms that create noticeable interference with daily functioning. It is indicated for conditions including Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), Panic Disorder, Bulimia Nervosa, and Premenstrual Dysphoric Disorder (PMDD).

Fluoxetina Nodepe is commonly used to help with symptom clusters such as persistent low mood, hopelessness, intrusive thoughts, and intense fear episodes. It helps maintain a sense of stability when symptoms are more noticeable, and is applied in clinical settings that involve acute or unstable symptom patterns.

“The primary goal of this supportive management is to may help patients cope more steadily with symptom fluctuations, particularly during phases of increased distress or discomfort.”

Quick Fact: Symptom Management for Persistent Mood, Compulsions, and Panic
Affective Distress (MDD) Supports emotional stabilization and helps ease overall symptom burden.
Intrusive Thoughts (OCD) Helps improve day-to-day comfort during symptomatic periods.
Acute Fear (Panic) Assists with maintaining functional stability when symptoms become difficult to tolerate.

Eligibility and Restrictions for Use

Fluoxetina Nodepe (fluoxetine) is an antidepressant medication that can be prescribed for a variety of conditions, including major depressive disorder, obsessive-compulsive disorder (OCD), bulimia nervosa, and panic disorder. It is generally suitable for most adults and, depending on the specific condition, may be used in children and adolescents, typically from ages 8 and up for depression and 7 and up for OCD.


However, Fluoxetina Nodepe is not suitable for everyone. The drug is contraindicated for patients who:

  • Have a known hypersensitivity or allergic reaction to fluoxetine or any component of the formulation.
  • Are currently taking or have recently taken (within the last 14 days) a Monoamine Oxidase Inhibitor (MAOI). A washout period is essential due to the risk of a serious drug interaction called serotonin syndrome.
  • Are taking pimozide or thioridazine.

Caution is required for individuals with pre-existing conditions, including heart problems (especially those leading to QT prolongation), seizure disorders (epilepsy), a history of mania or bipolar disorder, angle-closure glaucoma, bleeding disorders, unstable diabetes, or severe liver impairment. Use during pregnancy or breastfeeding requires a careful risk-benefit analysis by a healthcare professional.

What should I know about interactions with other medicines?

Interactions with other Medicines and Products

Fluoxetine (Fluoxetina Nodepe) has a documented interaction profile involving both pharmacokinetic (PK) and pharmacodynamic (PD) mechanisms, which necessitates careful consideration during co-administration.

Contraindicated Combinations

Co-administration is strictly prohibited with Monoamine Oxidase Inhibitors (MAOIs) intended for psychiatric disorders, including Linezolid and Intravenous Methylene Blue, due to the high risk of serotonin syndrome. Fluoxetine is also contraindicated with Pimozide and Thioridazine because of the potential for increased drug levels and serious cardiotoxicity.

Pharmacokinetic Interactions

Fluoxetine is a potent inhibitor of the CYP2D6 enzyme. This can lead to increased plasma concentrations of other medicines metabolized by CYP2D6, such as certain Tricyclic Antidepressants (TCAs), Antipsychotics, and some Antiarrhythmics. Increased levels of these co-administered drugs may necessitate monitoring.

Pharmacodynamic Interactions

Combining Fluoxetine with other serotonergic agents (including Triptans, Tramadol, and Lithium) significantly increases the risk of serotonin syndrome. Additionally, co-administration with agents that interfere with blood clotting, such as Warfarin, NSAIDs, and Aspirin, increases the documented risk of abnormal bleeding.

Timing and Separation Requirements

Due to the long half-life of Fluoxetine and its active metabolite, norfluoxetine, a 5-week washout period is required after discontinuing Fluoxetine before initiating an MAOI or Thioridazine to mitigate interaction risk.

Mechanism of Action

The mechanism of action for Fluoxetina Nodepe centers on modulating key pathways in the central nervous system. The drug is classified as a Selective Serotonin Reuptake Inhibitor (SSRI).

Selective Serotonin Reuptake Inhibition (SSRI)

Fluoxetina Nodepe acts by selectively binding to and blocking the Serotonin Transporter (SERT) protein located on presynaptic neurons. This molecular interaction prevents the reabsorption (reuptake) of the neurotransmitter serotonin (5-HT) from the synaptic cleft back into the neuron. This results in an increased concentration and duration of serotonin available to interact with postsynaptic receptors.

Long-Term Neural Pathway Adaptation

Sustained elevation of synaptic serotonin initiates complex adaptive feedback mechanisms within the neural network. This prolonged modulation induces a gradual shift in the sensitivity and activity profile of postsynaptic serotonin receptors. This mechanism modifies the signaling activity of targeted serotonergic pathways and leads to biochemical adjustments within the overall neurotransmitter system.

Dosage and Administration Information

Official Administration Guidelines

Fluoxetina Nodepe is administered exclusively by the oral route, available as immediate-release tablets or capsules, an oral solution, and a delayed-release 90 mg capsule for once-weekly use. The immediate-release forms are typically taken once daily, often in the morning, and can be administered with or without food, as food does not significantly affect the drug's absorption.

Standardized Dosing and Frequency

The regimen starts with a standardized initial dose, typically 20 mg daily for most conditions, including Major Depressive Disorder (MDD). Dosing may be adjusted after several weeks of use. Specialized regimens include a fixed 60 mg daily dose for Bulimia Nervosa and an intermittent schedule for Premenstrual Dysphoric Disorder (PMDD) tied to the menstrual cycle.

Usage Pattern Range / Rule
Maintenance Range 20 mg to 60 mg per day (Maximum 80 mg/ day)
Frequency Once daily, Once weekly (90 mg delayed-release), or Intermittent
Adjustment for Hepatic Impairment Lower or less frequent dose (e.g., 20 mg every other day)
Adjustment for Older Adults Lower daily dose; generally not to exceed 40 mg or 60 mg

Procedural and Contextual Instructions

When using the oral solution, the bottle must be shaken well prior to measurement. The transition from a daily regimen to the 90 mg once-weekly capsule requires that the weekly dose be started seven days after the patient’s last daily 20 mg dose. The administration protocol is defined by standardized oral delivery and precise timing.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Fluoxetina Nodepe

Evidence for use in Major Depressive Disorder (MDD)

Research examining Fluoxetina Nodepe for Major Depressive Disorder primarily consists of short-term randomized controlled trials (RCTs). These studies monitor outcomes related to systemic or functional imbalance, mainly by measuring changes in scores on specific scales completed by clinicians. Studies report how symptoms changed in the observed populations, and research provides insight into short-term changes, specifically within the initial months of use. Follow-up durations were limited in many primary studies, and what remains unclear is how the outcomes reflecting daily functioning change beyond the initial short-term trials.

Evidence for use in Obsessive-Compulsive Disorder (OCD)

Fluoxetina Nodepe was studied for Obsessive-Compulsive Disorder (OCD) in controlled trials, often involving both adult and pediatric subjects. The research examined outcomes related to episodic or acute changes by monitoring how the frequency and severity of OCD symptoms shifted. Findings indicate patterns related to short-term changes in these symptoms, and research describes that different study protocols were used in some studies for this condition.

Evidence for use in Bulimia Nervosa (BN)

Fluoxetina Nodepe was evaluated in randomized trials for patients with Bulimia Nervosa, a condition associated with acute or disruptive episodes of binging and purging behaviors. The research explored short-term symptom changes, typically over 8 to 16 weeks, focusing heavily on outcomes describing episodic or acute changes in the frequency of these core behaviors. Trials documented reported changes in the frequency of key behavioral events during the study period, primarily linked to the specific study protocols for this indication.

What is Still Uncertain About Fluoxetina Nodepe Research

Comparative evidence is lacking for many specific head-to-head comparisons against other commonly used medicines. Follow-up durations were limited in many primary trials, meaning the long-term changes in patient-reported outcomes describing perceived discomfort are not fully established. Additionally, results apply only to the populations studied, and data for certain groups, such as those with specific rare or complex co-occurring illnesses, remain insufficient.

Key Studies & References

  1. NICE Guideline NG222: Depression in adults: treatment and management (UK)

Frequently Asked Questions (FAQ)

Common questions about Fluoxetina Nodepe (FAQ)

Q: In simple terms, what does Fluoxetina Nodepe do in the brain?

Fluoxetina Nodepe is a Selective Serotonin Reuptake Inhibitor (SSRI). Official product information indicates that it works by increasing the levels of the chemical serotonin in the brain by slowing the reabsorption of serotonin into nerve cells. Serotonin is a neurotransmitter that is understood to have a positive influence on mood, emotion, and sleep.


Q: Does Fluoxetina Nodepe typically cause changes in body weight or appetite?

Changes in both appetite and body weight are documented in the official safety profile. Decreased appetite is listed as a commonly reported side effect. Studies show that some patients may experience initial weight loss, but long-term changes in body weight can often be similar to those seen with placebo.


Q: Are there any known long-term side effects that may occur with prolonged use of Fluoxetina Nodepe?

Official regulatory documents indicate that the effectiveness of Fluoxetina Nodepe in long-term use, specifically for periods longer than six months, has not been systematically evaluated in controlled clinical trials for all approved conditions. Safety documentation lists adverse effects based on clinical trials and post-marketing data, but does not isolate effects that only arise after years of continuous use.


Q: What is Serotonin Syndrome and what role does Fluoxetina Nodepe play in that risk?

Serotonin Syndrome is a potentially serious drug reaction caused by medications that lead to dangerously high levels of serotonin in the body. Symptoms can range from mild, such as shivering and confusion, to severe, including high fever and an irregular heartbeat. Fluoxetina Nodepe can cause or increase this risk, particularly if it is combined with other serotonergic medicines.


Q: How long does Fluoxetina Nodepe stay in the body after the last dose is taken?

The active substance fluoxetine has an elimination half-life of about 1 to 4 days. Its primary active metabolite, norfluoxetine, has a much longer half-life, ranging from seven to fifteen days. Due to this long half-life of the metabolite, the active drug can persist in the body for weeks after the last dose.


Q: What kind of liver or kidney function monitoring might be needed while taking Fluoxetina Nodepe?

Official guidelines note that Fluoxetina Nodepe is metabolized by the liver. Therefore, its half-life may be prolonged in individuals with liver disease. Its use in these individuals requires careful consideration of the dosage. Studies indicate that kidney impairment does not significantly affect the drug's concentration in the body.


Q: What are the signs of an allergic reaction that require immediate attention while on Fluoxetina Nodepe?

Official drug information emphasizes that the potential for an allergic reaction is a serious event noted in regulatory information. Signs may include skin rash, itching, hives, or swelling of the face, lips, tongue, or throat.


Q: How long does it usually take for a person to feel the full effects of Fluoxetina Nodepe?

Studies indicate that patients may see some initial symptom improvement after one to two weeks of starting treatment. However, it typically takes between four and six weeks to feel the full therapeutic benefits of the medication.


Q: Is there a maximum amount of time Fluoxetina Nodepe can be taken safely?

Official indications state that Fluoxetina Nodepe is used for both acute and maintenance treatment of several conditions. Regulatory documents note that the effectiveness for long-term use (more than six months) has not been systematically evaluated in controlled trials for all approved uses.


Q: Is it safe to consume alcoholic beverages while taking Fluoxetina Nodepe?

Official patient information regulatory information states that patients should limit or avoid the use of alcohol while taking fluoxetine. Alcohol can intensify nervous system side effects, potentially increasing issues like dizziness, drowsiness, and difficulty concentrating.


Q: What are the potential interactions between Fluoxetina Nodepe and herbal supplements like St. John’s Wort?

Regulatory sources note that the use of St. John’s wort is not recommended with Fluoxetina Nodepe. This combination significantly increases the risk of side effects, including the risk of dangerously elevated serotonin levels.


Q: Why is it generally recommended not to suddenly stop taking Fluoxetina Nodepe?

Regulatory documents contain a strong warning against abrupt discontinuation of this medication. Sudden cessation can lead to the experience of withdrawal reactions, which are officially reported in association with Selective Serotonin Reuptake Inhibitors (SSRIs).


Q: What are the common symptoms of 'discontinuation syndrome' when stopping Fluoxetina Nodepe?

Symptoms that may occur after stopping Fluoxetina Nodepe include nausea, dizziness, trouble sleeping, anxiety, headaches, and shaking. This collection of reactions is officially classified as antidepressant discontinuation syndrome.


Q: What is the purpose of gradually reducing the dose of Fluoxetina Nodepe (tapering)?

Gradual dose reduction is a strategy used to prevent or lessen the symptoms of antidepressant discontinuation syndrome. This approach mitigates the body's reaction to stopping the medication.


Q: Is the feeling of 'brain zaps' a possible discontinuation symptom of Fluoxetina Nodepe?

The discontinuation of SSRIs is associated with a category of reactions called sensory disturbances. This category includes electric-shock-like experiences (often referred to as 'brain zaps') that may occur when the medicine is stopped.


Q: Can Fluoxetina Nodepe affect alertness or the ability to drive or operate machinery?

Official drug information states that Fluoxetina Nodepe may cause drowsiness and affect a person’s judgment, thinking, and movements. Regulatory information contains a warning against driving or operating machinery until the individual knows how the medication affects them.

How should Fluoxetina Nodepe be stored and disposed of?

Official Storage and Disposal Requirements

Fluoxetine (Nodepe) must be stored according to strict regulatory guidelines to maintain potency and protect the environment.

Storage Conditions

  • Temperature: Store solid forms at controlled room temperature, typically 20 C to 25 C (68 F to 77 F).
  • Protection: Keep the medication in a tightly closed, light-resistant container, protecting it from excess heat and moisture.
  • Child Safety: All forms must be stored out of the sight and reach of children.

Stability and Disposal

  • Stability: Fluoxetine oral solution must be discarded 60 days after first opening.
  • Disposal: Do not throw away unused or expired medicine via wastewater or household waste. Consult a pharmacist for instructions on how to properly dispose of the medicine according to local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fluoxetina Nodepe found in:

A-Z Index: